(MENAFN- GlobeNewsWire - Nasdaq) A Comprehensive, Evidence-Based Review of GLP-1/GIP Agonists for fitness and Wellness Professionals Gilbert, AZ, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The National ...

Weight loss medications, including the widely recognized GLP-1 and GIP agonists, have become a popular solution for managing obesity in individuals with and without type 2 diabetes mellitus.

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Weight loss medications, including the widely recognized GLP-1 and GIP agonists, have become a popular solution for managing obesity in individuals with and without type 2 diabetes mellitus. As ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

"We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may result in additive and synergistic effects on patient weight loss, and importantly ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.